Acesso livre
Acesso livre

Medicina de Emergências

OMS recomenda bloqueadores do receptor de interleucina-6 para salvar vidas na COVID-19 e pressiona os produtores a unir forças para aumentar rapidamente o acesso – “Estes são os primeiros medicamentos que se demonstraram efetivos contra a COVID-19 desde que os corticosteroides foram recomendados pela OMS em setembro de 2020.”

7 Jul, 2021 | 08:11h

WHO recommends life-saving interleukin-6 receptor blockers for COVID-19 and urges producers to join efforts to rapidly increase access – World Health Organization

 

Comentário no Twitter (fio – clique para saber mais)

 

M-A | Plasma convalescente é seguro, mas não melhora os desfechos no tratamento da COVID-19.

7 Jul, 2021 | 08:07h

Systematic review and meta-analysis of randomised controlled trials testing the safety and efficacy of convalescent plasma in the treatment of coronavirus disease 2019 (COVID-19): Evidence-base for practise and implications for research – Transfusion Medicine

Diretrizes SAEM para cuidado razoável e adequado no departamentod e emergência (Guidelines for reasonable and appropriate care in the emergency department – GRACE): dor torácica recorrente e de baixo risco no departamento de emergência.

7 Jul, 2021 | 08:03h

Guidelines for reasonable and appropriate care in the emergency department (GRACE): Recurrent, low-risk chest pain in the emergency department – Academic Emergency Medicine

Comunicado de imprensa: SAEM publishes GRACE guidelines for recurrent, low-risk chest pain care in the ED – Society for Academic Emergency Medicine

Comentários convidados: GRACE-recurrent low-risk chest pain: A user’s guide E Navigating uncertainty with GRACE: Society for Academic Emergency Medicine’s guidelines for reasonable and appropriate care in the emergency department

 

Choosing Wisely para COVID-19: 10 recomendações baseadas em evidências para pacientes e médicos.

6 Jul, 2021 | 11:26h

Choosing Wisely for COVID-19: ten evidence-based recommendations for patients and physicians – Nature Medicine

Estudo randomizado | Ivermectina não evita hospitalização em pacientes com COVID-19.

6 Jul, 2021 | 11:24h

Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial – BMC Infectious Diseases

Comentário: Ivermectin: balance of evidence shows no significant benefit against Covid-19 – MSN News

Relacionado: Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – “IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease”. E Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”. E Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials E RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19

Editorial | Não fique aí sentado, faça alguma coisa… mas não cause dano: os aspectos preocupantes das intervenções experimentais contra a COVID-19.

6 Jul, 2021 | 11:23h

Do not just sit there, do something … but do no harm: the worrying aspects of COVID-19 experimental interventions – Intensive Care Medicine

 

Comentário no Twitter

 

Consenso da WSES | Diagnóstico e tratamento da obstrução do intestino delgado em abdome virgem/intacto.

6 Jul, 2021 | 11:17h

Diagnosis and management of small bowel obstruction in virgin abdomen: a WSES position paper – World Journal of Emergency Surgery

Relatório do CDC | Condições médicas subjacentes e risco de doença grave entre 540.667 adultos hospitalizados com COVID-19 entre março/2021 e março/2021.

5 Jul, 2021 | 10:31h

Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021 – Centers for Disease Control and Prevention

 

Comentário no Twitter

 

Trombocitopenia trombótica imune induzida por vacina (vaccine-induced immune thrombotic thrombocytopenia – VITT) – Uma nova entidade clinicopatológica com apresentações clínicas heterogêneas.

2 Jul, 2021 | 11:17h

Vaccine-induced immune thrombotic thrombocytopenia (VITT) – a novel clinico-pathological entity with heterogeneous clinical presentations – British Journal of Haematology

Comentário: Blood clots related to AstraZeneca/Oxford vaccine can be mitigated with early detection – MedicalXpress

Delirium na COVID-19

2 Jul, 2021 | 11:12h

Delirium in COVID-19: can we make the unknowns knowns? – Intensive Care Medicine

 

Comentário no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.